APO Research
Talk to an analyst

APO RESEARCH · REPORT

RNA Vaccines

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global RNA Vaccines Market Outlook and Growth Opportunities 2026

22 December 2025197 pages

Choose your research edition.

Industry ResearchRNA Vaccines Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal RNA Vaccines Industry Growth and Trends Forecast to 2032108 pages · $3,450 USDMarket StructureGlobal RNA Vaccines Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal RNA Vaccines Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal RNA Vaccines Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global RNA Vaccines market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for RNA Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for RNA Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for RNA Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the RNA Vaccines market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the RNA Vaccines market include Translate Bio, Tiba Biotechnology, Sangamo Therapeutics, Moderna Therapeutics, In-Cell-Art, Ethris, eTheRNA, CureVac and BioNTech, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global RNA Vaccines market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of RNA Vaccines and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents RNA Vaccines sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the RNA Vaccines market size, projected growth trends, production technologies, key applications, and end-use industries.

RNA Vaccines Segment by Company

Translate Bio

Tiba Biotechnology

Sangamo Therapeutics

Moderna Therapeutics

In-Cell-Art

Ethris

eTheRNA

CureVac

BioNTech

Argos Therapeutics

RNA Vaccines Segment by Type

Individualized Cancer Treatment MRNA Vaccine

Infection Prevention MRNA Vaccine

Infectious Disease Treatment MRNA Vaccine

RNA Vaccines Segment by Application

Infectious Disease

Cancer

Other

RNA Vaccines Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global RNA Vaccines status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions RNA Vaccines market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify RNA Vaccines significant trends, drivers, influence factors in global and regions.

6. To analyze RNA Vaccines competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global RNA Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of RNA Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of RNA Vaccines.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the RNA Vaccines market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global RNA Vaccines industry.

Chapter 3: Detailed analysis of RNA Vaccines manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of RNA Vaccines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of RNA Vaccines in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. RNA Vaccines Industry Trends Table 2. RNA Vaccines Industry Drivers Table 3. RNA Vaccines Industry Opportunities and Challenges Table 4. RNA Vaccines Industry Restraints Table 5. Global RNA Vaccines Revenue by Company (US$ Million) & (2021-2026) Table 6. Global RNA Vaccines Revenue Share by Company (2021-2026) Table 7. Global RNA Vaccines Sales Volume by Company (k units) & (2021-2026) Table 8. Global RNA Vaccines Sales Volume Share by Company (2021-2026) Table 9. Global RNA Vaccines Average Price (US$/unit) of Company (2021-2026) Table 10. Global RNA Vaccines Company Ranking, (2024-2026) & (USD Million) Table 11. Global RNA Vaccines Key Company Manufacturing Base & Headquarters Table 12. Global RNA Vaccines Company, Product Type & Application Table 13. Global RNA Vaccines Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global RNA Vaccines by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Individualized Cancer Treatment MRNA Vaccine Table 18. Significant Companies of Infection Prevention MRNA Vaccine Table 19. Significant Companies of Infectious Disease Treatment MRNA Vaccine Table 20. Global RNA Vaccines Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 21. Global RNA Vaccines Sales Volume by Type (2021-2026) & (k units) Table 22. Global RNA Vaccines Sales Volume by Type (2027-2032) & (k units) Table 23. Global RNA Vaccines Sales Volume Share by Type (2021-2026) Table 24. Global RNA Vaccines Sales Volume Share by Type (2027-2032) Table 25. Global RNA Vaccines Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global RNA Vaccines Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global RNA Vaccines Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global RNA Vaccines Sales Value Share by Type (2021-2026) Table 29. Global RNA Vaccines Sales Value Share by Type (2027-2032) Table 30. Significant Companies of Infectious Disease Table 31. Significant Companies of Cancer Table 32. Significant Companies of Other Table 33. Global RNA Vaccines Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 34. Global RNA Vaccines Sales Volume by Application (2021-2026) & (k units) Table 35. Global RNA Vaccines Sales Volume by Application (2027-2032) & (k units) Table 36. Global RNA Vaccines Sales Volume Share by Application (2021-2026) Table 37. Global RNA Vaccines Sales Volume Share by Application (2027-2032) Table 38. Global RNA Vaccines Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global RNA Vaccines Sales Value by Application (2021-2026) & (US$ Million) Table 40. Global RNA Vaccines Sales Value by Application (2027-2032) & (US$ Million) Table 41. Global RNA Vaccines Sales Value Share by Application (2021-2026) Table 42. Global RNA Vaccines Sales Value Share by Application (2027-2032) Table 43. Global RNA Vaccines Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 44. Global RNA Vaccines Sales by Region (2021-2026) & (k units) Table 45. Global RNA Vaccines Sales Market Share by Region (2021-2026) Table 46. Global RNA Vaccines Sales by Region (2027-2032) & (k units) Table 47. Global RNA Vaccines Sales Market Share by Region (2027-2032) Table 48. Global RNA Vaccines Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global RNA Vaccines Sales Value by Region (2021-2026) & (US$ Million) Table 50. Global RNA Vaccines Sales Value Share by Region (2021-2026) Table 51. Global RNA Vaccines Sales Value by Region (2027-2032) & (US$ Million) Table 52. Global RNA Vaccines Sales Value Share by Region (2027-2032) Table 53. Global RNA Vaccines Market Average Price (US$/unit) by Region (2021-2026) Table 54. Global RNA Vaccines Market Average Price (US$/unit) by Region (2027-2032) Table 55. Global RNA Vaccines Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 56. Global RNA Vaccines Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 57. Global RNA Vaccines Sales by Country (2021-2026) & (k units) Table 58. Global RNA Vaccines Sales Market Share by Country (2021-2026) Table 59. Global RNA Vaccines Sales by Country (2027-2032) & (k units) Table 60. Global RNA Vaccines Sales Market Share by Country (2027-2032) Table 61. Global RNA Vaccines Sales Value by Country (2021-2026) & (US$ Million) Table 62. Global RNA Vaccines Sales Value Market Share by Country (2021-2026) Table 63. Global RNA Vaccines Sales Value by Country (2027-2032) & (US$ Million) Table 64. Global RNA Vaccines Sales Value Market Share by Country (2027-2032) Table 65. Translate Bio Company Information Table 66. Translate Bio Business Overview Table 67. Translate Bio RNA Vaccines Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 68. Translate Bio RNA Vaccines Product Portfolio Table 69. Translate Bio Recent Development Table 70. Tiba Biotechnology Company Information Table 71. Tiba Biotechnology Business Overview Table 72. Tiba Biotechnology RNA Vaccines Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 73. Tiba Biotechnology RNA Vaccines Product Portfolio Table 74. Tiba Biotechnology Recent Development Table 75. Sangamo Therapeutics Company Information Table 76. Sangamo Therapeutics Business Overview Table 77. Sangamo Therapeutics RNA Vaccines Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 78. Sangamo Therapeutics RNA Vaccines Product Portfolio Table 79. Sangamo Therapeutics Recent Development Table 80. Moderna Therapeutics Company Information Table 81. Moderna Therapeutics Business Overview Table 82. Moderna Therapeutics RNA Vaccines Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 83. Moderna Therapeutics RNA Vaccines Product Portfolio Table 84. Moderna Therapeutics Recent Development Table 85. In-Cell-Art Company Information Table 86. In-Cell-Art Business Overview Table 87. In-Cell-Art RNA Vaccines Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 88. In-Cell-Art RNA Vaccines Product Portfolio Table 89. In-Cell-Art Recent Development Table 90. Ethris Company Information Table 91. Ethris Business Overview Table 92. Ethris RNA Vaccines Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 93. Ethris RNA Vaccines Product Portfolio Table 94. Ethris Recent Development Table 95. eTheRNA Company Information Table 96. eTheRNA Business Overview Table 97. eTheRNA RNA Vaccines Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 98. eTheRNA RNA Vaccines Product Portfolio Table 99. eTheRNA Recent Development Table 100. CureVac Company Information Table 101. CureVac Business Overview Table 102. CureVac RNA Vaccines Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 103. CureVac RNA Vaccines Product Portfolio Table 104. CureVac Recent Development Table 105. BioNTech Company Information Table 106. BioNTech Business Overview Table 107. BioNTech RNA Vaccines Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 108. BioNTech RNA Vaccines Product Portfolio Table 109. BioNTech Recent Development Table 110. Argos Therapeutics Company Information Table 111. Argos Therapeutics Business Overview Table 112. Argos Therapeutics RNA Vaccines Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 113. Argos Therapeutics RNA Vaccines Product Portfolio Table 114. Argos Therapeutics Recent Development Table 115. Key Raw Materials Table 116. Raw Materials Key Suppliers Table 117. RNA Vaccines Distributors List Table 118. RNA Vaccines Customers List Table 119. Research Programs/Design for This Report Table 120. Authors List of This Report Table 121. Secondary Sources Table 122. Primary Sources List of Figures Figure 1. RNA Vaccines Product Image Figure 2. Global RNA Vaccines Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global RNA Vaccines Sales Value (2021-2032) & (US$ Million) Figure 4. Global RNA Vaccines Sales (2021-2032) & (k units) Figure 5. Global RNA Vaccines Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global RNA Vaccines Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Individualized Cancer Treatment MRNA Vaccine Image Figure 10. Infection Prevention MRNA Vaccine Image Figure 11. Infectious Disease Treatment MRNA Vaccine Image Figure 12. Global RNA Vaccines Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 13. Global RNA Vaccines Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global RNA Vaccines Sales Volume Share by Type (2021-2032) Figure 15. Global RNA Vaccines Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global RNA Vaccines Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global RNA Vaccines Sales Value Share by Type (2021-2032) Figure 18. Infectious Disease Image Figure 19. Cancer Image Figure 20. Other Image Figure 21. Global RNA Vaccines Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 22. Global RNA Vaccines Sales Volume Share 2021 VS 2025 VS 2032 Figure 23. Global RNA Vaccines Sales Volume Share by Application (2021-2032) Figure 24. Global RNA Vaccines Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global RNA Vaccines Sales Value Share 2021 VS 2025 VS 2032 Figure 26. Global RNA Vaccines Sales Value Share by Application (2021-2032) Figure 27. Global RNA Vaccines Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 28. Global RNA Vaccines Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 29. Global RNA Vaccines Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 30. Global RNA Vaccines Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 31. North America RNA Vaccines Sales Value (2021-2032) & (US$ Million) Figure 32. North America RNA Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Europe RNA Vaccines Sales Value (2021-2032) & (US$ Million) Figure 34. Europe RNA Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Asia-Pacific RNA Vaccines Sales Value (2021-2032) & (US$ Million) Figure 36. Asia-Pacific RNA Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 37. South America RNA Vaccines Sales Value (2021-2032) & (US$ Million) Figure 38. South America RNA Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Middle East & Africa RNA Vaccines Sales Value (2021-2032) & (US$ Million) Figure 40. Middle East & Africa RNA Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 41. USA RNA Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. USA RNA Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. USA RNA Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Canada RNA Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Canada RNA Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Canada RNA Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Mexico RNA Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Mexico RNA Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Mexico RNA Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Germany RNA Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Germany RNA Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Germany RNA Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. France RNA Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. France RNA Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. France RNA Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. U.K. RNA Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. U.K. RNA Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. U.K. RNA Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Italy RNA Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Italy RNA Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Italy RNA Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Spain RNA Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Spain RNA Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Spain RNA Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Russia RNA Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Russia RNA Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Russia RNA Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Netherlands RNA Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Netherlands RNA Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Netherlands RNA Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Nordic Countries RNA Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Nordic Countries RNA Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Nordic Countries RNA Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. China RNA Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. China RNA Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. China RNA Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Japan RNA Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Japan RNA Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Japan RNA Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. South Korea RNA Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. South Korea RNA Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. South Korea RNA Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. India RNA Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. India RNA Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. India RNA Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Australia RNA Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Australia RNA Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Australia RNA Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Southeast Asia RNA Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Southeast Asia RNA Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Southeast Asia RNA Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Brazil RNA Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Brazil RNA Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Brazil RNA Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Argentina RNA Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Argentina RNA Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Argentina RNA Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Chile RNA Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Chile RNA Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Chile RNA Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Colombia RNA Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Colombia RNA Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Colombia RNA Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Peru RNA Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Peru RNA Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Peru RNA Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Saudi Arabia RNA Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Saudi Arabia RNA Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Saudi Arabia RNA Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Israel RNA Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Israel Arabia RNA Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Israel Arabia RNA Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. UAE RNA Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. UAE RNA Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. UAE RNA Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Turkey RNA Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Turkey RNA Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Turkey RNA Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Iran RNA Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Iran RNA Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Iran RNA Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Egypt RNA Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Egypt RNA Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Egypt RNA Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. RNA Vaccines Value Chain Figure 126. Manufacturing Cost Structure Figure 127. RNA Vaccines Sales Mode & Process Figure 128. Direct Comparison with Distribution Share Figure 129. Distributors Profiles Figure 130. Years Considered Figure 131. Research Process Figure 132. Key Executives Interviewed

Scope & coverage.

Types
  • Individualized Cancer Treatment MRNA Vaccine
  • Infection Prevention MRNA Vaccine
  • Infectious Disease Treatment MRNA Vaccine
Applications
  • Infectious Disease
  • Cancer
  • Other
Companies covered
  • Translate Bio
  • Tiba Biotechnology
  • Sangamo Therapeutics
  • Moderna Therapeutics
  • In-Cell-Art
  • Ethris
  • eTheRNA
  • CureVac
  • BioNTech
  • Argos Therapeutics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global RNA Vaccines Sales Value (2021-2032)
  4. 1.2.2 Global RNA Vaccines Sales Volume (2021-2032)
  5. 1.2.3 Global RNA Vaccines Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 RNA Vaccines Market Dynamics
  1. 2.1 RNA Vaccines Industry Trends
  2. 2.2 RNA Vaccines Industry Drivers
  3. 2.3 RNA Vaccines Industry Opportunities and Challenges
  4. 2.4 RNA Vaccines Industry Restraints
3 RNA Vaccines Market by Company
  1. 3.1 Global RNA Vaccines Company Revenue Ranking in 2025
  2. 3.2 Global RNA Vaccines Revenue by Company (2021-2026)
  3. 3.3 Global RNA Vaccines Sales Volume by Company (2021-2026)
  4. 3.4 Global RNA Vaccines Average Price by Company (2021-2026)
  5. 3.5 Global RNA Vaccines Company Ranking (2024-2026)
  6. 3.6 Global RNA Vaccines Company Manufacturing Base and Headquarters
  7. 3.7 Global RNA Vaccines Company Product Type and Application
  8. 3.8 Global RNA Vaccines Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global RNA Vaccines Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 RNA Vaccines Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 RNA Vaccines Market by Type
  1. 4.1 RNA Vaccines Type Introduction
  2. 4.1.1 Individualized Cancer Treatment MRNA Vaccine
  3. 4.1.2 Infection Prevention MRNA Vaccine
  4. 4.1.3 Infectious Disease Treatment MRNA Vaccine
  5. 4.2 Global RNA Vaccines Sales Volume by Type
  6. 4.2.1 Global RNA Vaccines Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global RNA Vaccines Sales Volume by Type (2021-2032)
  8. 4.2.3 Global RNA Vaccines Sales Volume Share by Type (2021-2032)
  9. 4.3 Global RNA Vaccines Sales Value by Type
  10. 4.3.1 Global RNA Vaccines Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global RNA Vaccines Sales Value by Type (2021-2032)
  12. 4.3.3 Global RNA Vaccines Sales Value Share by Type (2021-2032)
5 RNA Vaccines Market by Application
  1. 5.1 RNA Vaccines Application Introduction
  2. 5.1.1 Infectious Disease
  3. 5.1.2 Cancer
  4. 5.1.3 Other
  5. 5.2 Global RNA Vaccines Sales Volume by Application
  6. 5.2.1 Global RNA Vaccines Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global RNA Vaccines Sales Volume by Application (2021-2032)
  8. 5.2.3 Global RNA Vaccines Sales Volume Share by Application (2021-2032)
  9. 5.3 Global RNA Vaccines Sales Value by Application
  10. 5.3.1 Global RNA Vaccines Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global RNA Vaccines Sales Value by Application (2021-2032)
  12. 5.3.3 Global RNA Vaccines Sales Value Share by Application (2021-2032)
6 RNA Vaccines Regional Sales and Value Analysis
  1. 6.1 Global RNA Vaccines Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global RNA Vaccines Sales by Region (2021-2032)
  3. 6.2.1 Global RNA Vaccines Sales by Region: 2021-2026
  4. 6.2.2 Global RNA Vaccines Sales by Region (2027-2032)
  5. 6.3 Global RNA Vaccines Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global RNA Vaccines Sales Value by Region (2021-2032)
  7. 6.4.1 Global RNA Vaccines Sales Value by Region: 2021-2026
  8. 6.4.2 Global RNA Vaccines Sales Value by Region (2027-2032)
  9. 6.5 Global RNA Vaccines Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America RNA Vaccines Sales Value (2021-2032)
  12. 6.6.2 North America RNA Vaccines Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe RNA Vaccines Sales Value (2021-2032)
  15. 6.7.2 Europe RNA Vaccines Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific RNA Vaccines Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific RNA Vaccines Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America RNA Vaccines Sales Value (2021-2032)
  21. 6.9.2 South America RNA Vaccines Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa RNA Vaccines Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa RNA Vaccines Sales Value Share by Country, 2025 VS 2032
7 RNA Vaccines Country-level Sales and Value Analysis
  1. 7.1 Global RNA Vaccines Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global RNA Vaccines Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global RNA Vaccines Sales by Country (2021-2032)
  4. 7.3.1 Global RNA Vaccines Sales by Country (2021-2026)
  5. 7.3.2 Global RNA Vaccines Sales by Country (2027-2032)
  6. 7.4 Global RNA Vaccines Sales Value by Country (2021-2032)
  7. 7.4.1 Global RNA Vaccines Sales Value by Country (2021-2026)
  8. 7.4.2 Global RNA Vaccines Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA RNA Vaccines Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA RNA Vaccines Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA RNA Vaccines Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada RNA Vaccines Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada RNA Vaccines Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada RNA Vaccines Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico RNA Vaccines Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico RNA Vaccines Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico RNA Vaccines Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany RNA Vaccines Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany RNA Vaccines Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany RNA Vaccines Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France RNA Vaccines Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France RNA Vaccines Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France RNA Vaccines Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. RNA Vaccines Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. RNA Vaccines Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. RNA Vaccines Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy RNA Vaccines Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy RNA Vaccines Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy RNA Vaccines Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain RNA Vaccines Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain RNA Vaccines Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain RNA Vaccines Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia RNA Vaccines Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia RNA Vaccines Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia RNA Vaccines Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands RNA Vaccines Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands RNA Vaccines Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands RNA Vaccines Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries RNA Vaccines Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries RNA Vaccines Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries RNA Vaccines Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China RNA Vaccines Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China RNA Vaccines Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China RNA Vaccines Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan RNA Vaccines Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan RNA Vaccines Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan RNA Vaccines Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea RNA Vaccines Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea RNA Vaccines Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea RNA Vaccines Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India RNA Vaccines Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India RNA Vaccines Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India RNA Vaccines Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia RNA Vaccines Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia RNA Vaccines Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia RNA Vaccines Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia RNA Vaccines Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia RNA Vaccines Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia RNA Vaccines Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil RNA Vaccines Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil RNA Vaccines Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil RNA Vaccines Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina RNA Vaccines Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina RNA Vaccines Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina RNA Vaccines Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile RNA Vaccines Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile RNA Vaccines Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile RNA Vaccines Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia RNA Vaccines Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia RNA Vaccines Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia RNA Vaccines Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru RNA Vaccines Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru RNA Vaccines Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru RNA Vaccines Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia RNA Vaccines Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia RNA Vaccines Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia RNA Vaccines Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel RNA Vaccines Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel RNA Vaccines Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel RNA Vaccines Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE RNA Vaccines Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE RNA Vaccines Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE RNA Vaccines Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey RNA Vaccines Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey RNA Vaccines Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey RNA Vaccines Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran RNA Vaccines Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran RNA Vaccines Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran RNA Vaccines Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt RNA Vaccines Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt RNA Vaccines Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt RNA Vaccines Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Translate Bio
  2. 8.1.1 Translate Bio Company Information
  3. 8.1.2 Translate Bio Business Overview
  4. 8.1.3 Translate Bio RNA Vaccines Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Translate Bio RNA Vaccines Product Portfolio
  6. 8.1.5 Translate Bio Recent Developments
  7. 8.2 Tiba Biotechnology
  8. 8.2.1 Tiba Biotechnology Company Information
  9. 8.2.2 Tiba Biotechnology Business Overview
  10. 8.2.3 Tiba Biotechnology RNA Vaccines Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Tiba Biotechnology RNA Vaccines Product Portfolio
  12. 8.2.5 Tiba Biotechnology Recent Developments
  13. 8.3 Sangamo Therapeutics
  14. 8.3.1 Sangamo Therapeutics Company Information
  15. 8.3.2 Sangamo Therapeutics Business Overview
  16. 8.3.3 Sangamo Therapeutics RNA Vaccines Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Sangamo Therapeutics RNA Vaccines Product Portfolio
  18. 8.3.5 Sangamo Therapeutics Recent Developments
  19. 8.4 Moderna Therapeutics
  20. 8.4.1 Moderna Therapeutics Company Information
  21. 8.4.2 Moderna Therapeutics Business Overview
  22. 8.4.3 Moderna Therapeutics RNA Vaccines Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Moderna Therapeutics RNA Vaccines Product Portfolio
  24. 8.4.5 Moderna Therapeutics Recent Developments
  25. 8.5 In-Cell-Art
  26. 8.5.1 In-Cell-Art Company Information
  27. 8.5.2 In-Cell-Art Business Overview
  28. 8.5.3 In-Cell-Art RNA Vaccines Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 In-Cell-Art RNA Vaccines Product Portfolio
  30. 8.5.5 In-Cell-Art Recent Developments
  31. 8.6 Ethris
  32. 8.6.1 Ethris Company Information
  33. 8.6.2 Ethris Business Overview
  34. 8.6.3 Ethris RNA Vaccines Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Ethris RNA Vaccines Product Portfolio
  36. 8.6.5 Ethris Recent Developments
  37. 8.7 eTheRNA
  38. 8.7.1 eTheRNA Company Information
  39. 8.7.2 eTheRNA Business Overview
  40. 8.7.3 eTheRNA RNA Vaccines Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 eTheRNA RNA Vaccines Product Portfolio
  42. 8.7.5 eTheRNA Recent Developments
  43. 8.8 CureVac
  44. 8.8.1 CureVac Company Information
  45. 8.8.2 CureVac Business Overview
  46. 8.8.3 CureVac RNA Vaccines Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 CureVac RNA Vaccines Product Portfolio
  48. 8.8.5 CureVac Recent Developments
  49. 8.9 BioNTech
  50. 8.9.1 BioNTech Company Information
  51. 8.9.2 BioNTech Business Overview
  52. 8.9.3 BioNTech RNA Vaccines Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 BioNTech RNA Vaccines Product Portfolio
  54. 8.9.5 BioNTech Recent Developments
  55. 8.10 Argos Therapeutics
  56. 8.10.1 Argos Therapeutics Company Information
  57. 8.10.2 Argos Therapeutics Business Overview
  58. 8.10.3 Argos Therapeutics RNA Vaccines Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Argos Therapeutics RNA Vaccines Product Portfolio
  60. 8.10.5 Argos Therapeutics Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 RNA Vaccines Value Chain Analysis
  2. 9.1.1 RNA Vaccines Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 RNA Vaccines Sales Mode & Process
  6. 9.2 RNA Vaccines Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 RNA Vaccines Distributors
  9. 9.2.3 RNA Vaccines Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst